Financing
Stock Issuance Proceeds
Regeneron Pharmaceuticals Stock Issuance Proceeds decreased by 67.6% to $163.10M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 169.1%, from $60.60M to $163.10M. Over 4 years (FY 2021 to FY 2025), Stock Issuance Proceeds shows a downward trend with a -21.5% CAGR.
Analysis
StatementCash Flow Statement
SectionFinancing
CategoryCapital Allocation
SignalContext dependent
VolatilityStable
First reportedQ1 2013
Last reportedQ1 2026Apr 29, 2026
How to read this metric
Higher proceeds often correlate with employee participation in stock-based compensation programs rather than external capital raising.
Detailed definition
Cash inflows resulting from the issuance of common stock, typically through employee stock option exercises or equity co...
Peer comparison
Standard for large-cap companies with significant equity-based compensation programs.
Metric ID:
proceeds_from_stock_issuanceHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $213.20M | $821.40M | $542.70M | $521.60M | $306.80M | $318.50M | $372.60M | $485.20M | $90.70M | $268.60M | $301.00M | $682.10M | $437.60M | $254.70M | $90.90M | $60.60M | $31.50M | $40.30M | $503.50M | $163.10M |
| QoQ Change | — | +285.3% | -33.9% | -3.9% | -41.2% | +3.8% | +17.0% | +30.2% | -81.3% | +196.1% | +12.1% | +126.6% | -35.8% | -41.8% | -64.3% | -33.3% | -48.0% | +27.9% | >999% | -67.6% |
| YoY Change | — | — | — | — | +43.9% | -61.2% | -31.3% | -7.0% | -70.4% | -15.7% | -19.2% | +40.6% | +382.5% | -5.2% | -69.8% | -91.1% | -92.8% | -84.2% | +453.9% | +169.1% |
Range$31.50M – $821.40M
CAGR-5.5%
Avg YoY Growth+33.9%
Median YoY Growth-17.4%
Stock Issuance Proceeds at Other Companies
Frequently Asked Questions
- What is Regeneron Pharmaceuticals's stock issuance proceeds?
- Regeneron Pharmaceuticals (REGN) reported stock issuance proceeds of $163.10M in Q1 2026.
- How has Regeneron Pharmaceuticals's stock issuance proceeds changed year-over-year?
- Regeneron Pharmaceuticals's stock issuance proceeds increased by 169.1% year-over-year, from $60.60M to $163.10M.
- What is the long-term trend for Regeneron Pharmaceuticals's stock issuance proceeds?
- Over 4 years (2021 to 2025), Regeneron Pharmaceuticals's stock issuance proceeds has grown at a -21.5% compound annual growth rate (CAGR), from $1.67B to $635.90M.
- What does stock issuance proceeds mean?
- Cash received from the sale or issuance of company stock.